Difference between revisions of "Trifluridine and tipiracil (Lonsurf)"
(FDA approval) |
m |
||
Line 33: | Line 33: | ||
[[Category:Pyrimidine analogues]] | [[Category:Pyrimidine analogues]] | ||
− | |||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
[[Category:Drugs FDA approved in 2015]] | [[Category:Drugs FDA approved in 2015]] |
Revision as of 15:04, 29 January 2017
General information
Class/mechanism: Combination of a thymidine-based (pyrimidine) nucleoside analog, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio 1:0.471). Tipriacil inhibits the metabolism of trifluridine by thymidine phosphorylase, which increases the exposure of cancer cells to trifluridine. The thymidine-based nucleoside analog trifluridine is incorporated into DNA and disrupts DNA synthesis and cell proliferation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 9/22/2015: FDA approved "for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy."
Also known as
- TAS-102
- Trifluridine/tipiracil
- Trifluridine & tipiracil